Table 2.
Cases (positive/total LN; pN stage) and positive BRAFVE on LN | Size of largest metastatic focus, ENE | Tumor size; histology; focality | BRAFVE on PTC | FNA category of PTC | NIFTP size | FNA category of NIFTP | Molecular testing on NIFTP | BRAFVE immunostain on NIFTP |
---|---|---|---|---|---|---|---|---|
Case 1 (2/16; pN1a) | 0.2 cm, no ENE | 4.2 cm; PTC; classic; multifocal | Positive | VI | 0.5 | — | — | Not performed |
Case 2 (2/7; pN1a) | 2.2 cm, no ENE | 1.9 cm; PTC; infiltrative follicular; multifocal | Positive | VI | 4.5 | III | — | Not performed |
Case 3 (3/8; pN1b) | 3.7 cm, no ENE | 4.5 cm; PTC; tall cell; multifocal | Positive | V | 1.3 | — | — | Negative |
Case 4 (5/15) | 3.8 cm with ENE, 0.3 cm | 1.4 cm; with diffuse sclerosing features; multifocal | Positive | VI | 1.2 | — | — | Negative |
Case 5a (1/3) | 0.8 cm, no ENE | NA | NA | NA | 5.5 | II | — | Not performed |
Case 6a (4/5) | 1.3 cm, with ENE, 0.1 cm | NA | NA | NA | 3.7 | III | Afirma suspicious | Negative |
Two cases presented with PTC metastatic to lymph nodes without primary thyroid PTC.
ENE, extranodal extension; LN, lymph nodes; NA, not applicable.